Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | DHPS | P49366 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 4/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.36 |
| ▸ | ESR1 | P03372 | 5/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21196087 | 0.79 | TRPA1 (0.41) | TRPA1IDO1AXLNOS1ESR2 | |
| SCHEMBL20439436 | 0.77 | TRPA1 (0.42) | TRPA1IDO1AXLNOS1ESR2 | |
| SCHEMBL17030759 | 0.77 | IDO1 (0.41) | TRPA1DHPSIDO1AXLNOS1 | |
| SCHEMBL24373847 | 0.76 | NOS1 (0.46) | TRPA1IDO1AXLNOS1ESR2 | |
| SCHEMBL22967212 | 0.76 | NOS1 (0.46) | TRPA1IDO1AXLNOS1ESR2 | |
| SCHEMBL23685818 | 0.76 | TRPA1 (0.44) | TRPA1IDO1AXLNOS1ESR2 | |
| SCHEMBL18133835 | 0.76 | NOS1 (0.50) | TRPA1DHPSIDO1AXLNOS1 | |
| SCHEMBL17030763 | 0.76 | AXL (0.42) | TRPA1DHPSIDO1AXLNOS1 | |
| SCHEMBL22967876 | 0.73 | AXL (0.56) | TRPA1IDO1AXLNOS1ESR2 | |
| SCHEMBL21938210 | 0.73 | IDO1 (0.38) | TRPA1IDO1AXLNOS1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | TRPA1 4854/4885DHPS 3759/4885IDO1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.